ORPHAGEN PHARMACEUTICALS, INC. SBIR Phase II Award, August 2019
A SBIR Phase II contract was awarded to Orphagen Pharmaceuticals in August, 2019 for $1,093,784.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
Currently, there are no issues on this topic.
Find more entities like ORPHAGEN PHARMACEUTICALS, INC. SBIR Phase II Award, August 2019
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.